Call Us Toll Free: 1-800-388-9993

_______________________

Dear DRIP Investors,


We have been helping people enroll in DRIPs since 1986. Many of our subscribers have written to express their thanks and describe the outcome of their DRIP investments. It has been a source of pride and our great pleasure to have assisted in your efforts to secure financial security.


However, after 35 years we have decided to stop fulfilling orders for enrollments after the March cycle. Moneypaper, via the directinvesting.com website, will continue to provide information about DRIPs and the enrollment process.


As always, good luck,

Vita Nelson


 

 

 

 

AbbVie Inc. (ABBV)

Available from the Temper Enrollment Service: No


Last Update On: 01/07/2021:

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases SKYRIZI to treat moderate to severe plaque psoriasis in adults RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV) TECHNIVIE to treat adults with genotype 4 HCV infection and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease KALETRA, a prescription anti-HIV-1 medicine CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency Synthroid used in the treatment of hypothyroidism AndroGel for males diagnosed with symptomatic low testosterone and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC Alector, Inc. Janssen Biotech, Inc. Frontier Medicines, Corp. Jacobio Pharmaceuticals I-Mab and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois. **Taken from Yahoo Finance**

Industry: Drugs, health care
Minimum Investment: $25.00
Maximum Investment: $150,000/year
Shares to qualify: 1
Recent Price: 109.03
Investing Fee: $0!
Fee for Dividends: $0!

! = Company pays fees

Information is based on an annual survey and updated when company changes become available.

Click for Español

FOR MORE
INFORMATION

And a free copy of The Moneypaper's direct investing brochure, please enter your contact information below.

You will also be signed up to receive our monthly stock special.

You can unsubscribe at any time. We do not share your email with anyone.

By email, you get the Monthly “Stock Special,” where the service fee for enrollment in a great DRIP stock is reduced.

* Required Field.